Hagens Berman said it has opened an investigation into CVRx Inc. over potential federal securities law violations after the medical device company disclosed a U.S. Department of Justice Civil Investigative Demand, lowered its 2026 revenue outlook, reported disruption in its commercial sales force, and then terminated Chief Revenue Officer Robert John. CVRx said the DOJ demand, received on May 14, 2026, is examining whether the company caused false claims to government health programs through improper Barostim marketing, kickbacks to healthcare providers, or false information submissions. The law firm also pointed to a sharp deterioration in Medicare Advantage approvals, with a primary payer's 30-day prior-authorization approval rate falling from 80% historically to 25%, and noted that CVRx shares fell 59% on August 7, 2026 after the disclosures.